Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Synereca Pharmaceuticals logo — Pioneering orally active drugs to rejuvenate antibiotic effi...

Synereca Pharmaceuticals

Pioneering orally active drugs to rejuvenate antibiotic efficacy against lung, urinary tract, and skin infections, as well as weaponizable pathogens.

Founded 2009 Venture round Total: $2.34M Biotechnology, Health Care +1

General Information

Company Name Synereca Pharmaceuticals
Founded Year 2009
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Synereca Pharmaceuticals. To contact Synereca Pharmaceuticals, visit synereca.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Synereca Pharmaceuticals compare?

A PDF of Synereca Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Synereca Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Synereca Pharmaceuticals

Synereca Pharmaceuticals is a biotechnology startup that focuses on the development of orally active drugs to enhance the efficacy of existing antibiotics. Founded in 2009 and based in Chapel Hill, North Carolina, the company's product line includes prototypic RecA inhibitors, targeting a wide range of pathogenic bacteria such as E. coli associated with lung, urinary tract, and skin infections, as well as weaponizable gram-positive and gram-negative pathogens. The company received a $600.00KVenture Round investment on 04 August 2015, with i2E, Accele Venture Partners, and Oklahoma Seed Capital Fund being the major investors. Synereca Pharmaceuticals aims to address the critical need for new approaches to combat antibiotic resistance and enhance the effectiveness of antibiotics in treating various infections.

Business keywords: pharmaceuticals, drug development, antibiotics, infectious diseases, bacterial infections, RecA inhibitors, pathogenic bacteria, E. coli, lung infections, urinary tract infections, skin infections, gram-positive bacteria, gram-negative bacteria, bactericidal antibiotics

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $600.00K 3
i2E
i2E, Accele Venture Partners +1
04 Aug 2015
Debt Financing $1.40M 2
i2E
i2E, Accele Venture Partners
16 Sep 2014
Venture Round $340.00K -
08 Feb 2011

Synereca Pharmaceuticals Alternatives & Competitors

View All Alternatives
Synereca Pharmaceuticals vs
Zikani Therapeutics
Zikani Therapeutics

A new era in antibiotic treatment targeting resilient gram-negative bacteria, delivering advanced or...

Series A
Biotechnology, Life Sciences
Synereca Pharmaceuticals vs
Prokaryotics, Inc.
Prokaryotics, Inc. United States

Antibacterial discovery organization committed to bringing forth innovative therapeutics to address...

8 employees
Biopharma, Biotechnology
Synereca Pharmaceuticals vs
Sealife PHARMA® GMBH
Sealife PHARMA® GMBH

Pioneering breakthroughs in marine biochemistry to combat drug-resistant infections and advance the...

Seed
Biotechnology, Health Care
Also compare with: Synereca Pharmaceuticals vs Melinta Therapeutics Melinta Therapeutics View all alternatives

FAQ About Synereca Pharmaceuticals

Pioneering orally active drugs to rejuvenate antibiotic efficacy against lung, urinary tract, and skin infections, as well as weaponizable pathogens.
Synereca Pharmaceuticals was founded in 2009.
Synereca Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceuticals, drug development, antibiotics and infectious diseases.
Synereca Pharmaceuticals has completed 3 funding rounds, raising a total of $2.34M. The latest funding stage is Venture round.
Top alternatives and competitors to Synereca Pharmaceuticals include Zikani Therapeutics, Prokaryotics, Inc., Sealife PHARMA® GMBH, Curza, Tetraphase Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Synereca Pharmaceuticals and Zikani Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Synereca Pharmaceuticals, https://bouncewatch.com/company/synereca-pharmaceuticals, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout